ClinicalTrials.gg
CompletedNCT02089659Updated Dec 28, 2018Results posted

A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)

A Phase 1 interventional study of Doravirine in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study aimed to investigate the influence of hepatic insufficiency on the pharmacokinetics (PK) of doravirine (MK-1439). In Part 1, PK of doravirine in participants with moderate hepatic insufficiency was compared with that of healthy control subjects matched with regard to mean age and weight. If a clinically meaningful increase in exposure of doravirine was observed in participants with moderate hepatic insufficiency in Part 1, study Part 2 was to evaluate PK of doravirine in participants with mild hepatic insufficiency.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 19 and 40 kg/m\^2
  • Continuous non-smoker or moderate smoker of \<20 cigarettes or equivalent per day. Agrees to consume \<=10 cigarettes or equivalent per day from the time of screening through the period of sample collection.
  • In good health and with no abnormality
  • Hepatic impairment participants: diagnosis of chronic (>6 months), stable hepatic insufficiency with features of cirrhosis due to any etiology. Part 1 only: score of 7 to 9 on the scale. Part 2: score of 5 to 6 on the Child-Pugh scale.
  • Females of : sexually inactive for >=14 days before study drug administration and throughout the study, or using 2 acceptable methods of barrier from screening until 14 days after study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Mentally or legally incapacitated or has significant emotional problems at the time of screening or expected during the study
  • History or presence of medical or psychiatric condition or disease
  • History or presence of drug abuse within the past 2 years
  • History or presence of or idiosyncratic reaction to the study drug or related compounds
  • Female participant who is pregnant or lactating
  • Positive results for breath alcohol or urine drug screen (unless due to prescription drug use and is approved by the investigator) at screening
  • Positive for at screening
  • Unable to refrain from or anticipates the use of any drug known to be a significant inhibitor or inducer of cytochrome oxidase or P-glycoprotein, or any medication or substance which cannot be discontinued at least 14 days before study drug administration and throughout the study.
  • Donation of >500 mL of blood or had significant blood loss within 56 days before study drug administration
  • Plasma donation within 7 days before study drug administration
  • Dosed in another clinical trial within 28 days before study drug administration
  • Healthy control participants only: positive for surface antigen (HBsAg) or virus (HCV) at screening;
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Part 1: Moderate Hepatic Insufficiency

    Participants with moderate hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have moderate hepatic insufficiency based on the Child-Pugh scale.

    Drug: Doravirine

  • Experimental
    Part 1: Healthy Matched Control

    Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine on Day 1 of Part 1.

    Drug: Doravirine

  • Experimental
    Part 2: Mild Hepatic Insufficiency

    Participants with mild hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have mild hepatic insufficiency based on the Child-Pugh scale. This arm was to be enrolled and investigated only if a clinically meaningful increase in exposure of doravirine was observed in participants with moderate hepatic insufficiency in Part 1.

    Drug: Doravirine

Interventions

  • Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally

    Also known as: MK-1439

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine

    Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 6, 12, 24, 48, and 72 hours postdose for all participants and at 96, 120, and 144 hours postdose for participants with hepatic insufficiency

  2. Maximum Observed Plasma Concentration (Cmax) of Doravirine

    Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 6, 12, 24, 48, and 72 hours postdose for all participants and at 96, 120, and 144 hours postdose for participants with hepatic insufficiency

  3. Area Under the Plasma Concentration Versus Time Curve Form 0 to 24 Hours (AUC0-24) of Doravirine

    Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 6, 12, and 24 hours postdose

  4. Plasma Concentration of Doravirine at 24 Hours (C24)

    Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method

    Time frame: 24 hours postdose

07

Results

Posted Dec 28, 2018

Participant flow

Part 2 of the study was to enroll participants only if a clinically meaningful increase in exposure of doravirine was observed in participants with moderate hepatic insufficiency in Part 1. Because this was not observed, no participants were enrolled in Part 2 of the study.

Participant flow — Overall Study
MilestonePart 1: Participants With Moderate Hepatic InsufficiencyPart 1: Healthy Control ParticipantsPart 2: Participants With Mild Hepatic Insufficiency
Started880
Completed880
Not completed000

Outcome measures

PrimaryArea Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine

Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 6, 12, 24, 48, and 72 hours postdose for all participants and at 96, 120, and 144 hours postdose for participants with hepatic insufficiency
Reported as:
Geometric mean · µM*hr
Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine
µM*hrPart 1: Participants With Moderate Hepatic InsufficiencyPart 1: Healthy Control Participants
Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine53.9 (41.5 to 70.0)54.6 (42.1 to 71.0)
Statistical analysis
  • Part 1: Participants With Moderate Hepatic Insufficiency vs Part 1: Healthy Control Participants · Geometric mean ratio: 0.99 · 90% CI 0.72 to 1.35Moderate hepatic insufficiency / Healthy controls
PrimaryMaximum Observed Plasma Concentration (Cmax) of Doravirine

Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 6, 12, 24, 48, and 72 hours postdose for all participants and at 96, 120, and 144 hours postdose for participants with hepatic insufficiency
Reported as:
Geometric mean · nM
Maximum Observed Plasma Concentration (Cmax) of Doravirine
nMPart 1: Participants With Moderate Hepatic InsufficiencyPart 1: Healthy Control Participants
Maximum Observed Plasma Concentration (Cmax) of Doravirine1850 (1420 to 2420)2050 (1570 to 2680)
Statistical analysis
  • Part 1: Participants With Moderate Hepatic Insufficiency vs Part 1: Healthy Control Participants · Geometric mean ratio: 0.90 · 90% CI 0.66 to 1.24Moderate hepatic insufficiency / Healthy controls
PrimaryArea Under the Plasma Concentration Versus Time Curve Form 0 to 24 Hours (AUC0-24) of Doravirine

Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 6, 12, and 24 hours postdose
Reported as:
Geometric mean · µM*hr
Area Under the Plasma Concentration Versus Time Curve Form 0 to 24 Hours (AUC0-24) of Doravirine
µM*hrPart 1: Participants With Moderate Hepatic InsufficiencyPart 1: Healthy Control Participants
Area Under the Plasma Concentration Versus Time Curve Form 0 to 24 Hours (AUC0-24) of Doravirine28.5 (23.4 to 34.8)30.6 (25.1 to 37.3)
Statistical analysis
  • Part 1: Participants With Moderate Hepatic Insufficiency vs Part 1: Healthy Control Participants · Geometric mean ratio: 0.93 · 90% CI 0.74 to 1.18Moderate hepatic insufficiency / Healthy controls
PrimaryPlasma Concentration of Doravirine at 24 Hours (C24)

Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method

Time frame:
24 hours postdose
Reported as:
Geometric mean · nM
Plasma Concentration of Doravirine at 24 Hours (C24)
nMPart 1: Participants With Moderate Hepatic InsufficiencyPart 1: Healthy Control Participants
Plasma Concentration of Doravirine at 24 Hours (C24)842 (658 to 1080)847 (662 to 1080)
Statistical analysis
  • Part 1: Participants With Moderate Hepatic Insufficiency vs Part 1: Healthy Control Participants · Geometric mean ratio: 0.99 · 90% CI 0.74 to 1.33Moderate hepatic insufficiency / Healthy controls

Adverse events

Collected over Up to 14 days after drug administration. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Participants With Moderate Hepatic Insufficiency0/8 (0%)0/8 (0%)4/8 (50%)
Part 1: Healthy Control Participants0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Most frequent other events
EventPart 1: Participants With Moderate Hepatic InsufficiencyPart 1: Healthy Control Participants
HeadacheNervous system disorders0/82/8
Dry mouthGastrointestinal disorders1/80/8
VomitingGastrointestinal disorders1/80/8
Back painMusculoskeletal and connective tissue disorders0/81/8
Dizziness posturalNervous system disorders1/80/8
SomnolenceNervous system disorders1/80/8

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(Years)Part 1: Participants With Moderate Hepatic InsufficiencyPart 1: Healthy Control ParticipantsTotal
Mean59 (54 to 64)56 (44 to 63)57 (44 to 64)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Participants With Moderate Hepatic InsufficiencyPart 1: Healthy Control ParticipantsTotal
Female224
Male6612
Child-Pugh Total Score
Child-Pugh Total Score(Participants)Part 1: Participants With Moderate Hepatic InsufficiencyPart 1: Healthy Control ParticipantsTotal
Total Score = 7202
Total Score = 8404
Total Score = 9202
Weight
Weight(kg)Part 1: Participants With Moderate Hepatic InsufficiencyPart 1: Healthy Control ParticipantsTotal
Mean82.0 (55.6 to 119.0)79.8 (66.0 to 92.1)80.9 (55.6 to 119.0)
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Khalilieh S, Yee KL, Liu R, Fan L, Sanchez RI, Auger P, Triantafyllou I, Stypinski D, Lasseter KC, Marbury T, Iwamoto M. Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics. J Clin Pharmacol. 2017 Jun;57(6):777-783. doi: 10.1002/jcph.857. Epub 2016 Dec 27. PubMed 28026013 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinicaltrials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in May 2014, 1 month.

Results were first posted in Dec 2018, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2014
First posted
Mar 18, 2014
StartActual
Mar 26, 2014
Primary completionActual
May 12, 2014
CompletionActual
May 12, 2014
Results first posted
Dec 28, 2018
Last update
Dec 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02089659
Responsible party
Sponsor
First posted
Mar 18, 2014
Start date
Mar 26, 2014
Primary completion
May 12, 2014
Completion
May 12, 2014
Results posted
Dec 28, 2018
Last update
Dec 28, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doravirine

Start the discussion